| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgement to Reviewers 2015
|
|
|
2016
|
93 |
C |
p. 104-106
3 p.
|
artikel
|
| 2 |
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806)
|
Lim, Sun Min
|
|
2016
|
93 |
C |
p. 1-8
8 p.
|
artikel
|
| 3 |
Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer
|
Hirose, Takashi
|
|
2016
|
93 |
C |
p. 69-76
8 p.
|
artikel
|
| 4 |
Cigarette smoke extract exposure induces EGFR-TKI resistance in EGFR-mutated NSCLC via mediating Src activation and EMT
|
Li, Dandan
|
|
2016
|
93 |
C |
p. 35-42
8 p.
|
artikel
|
| 5 |
Contents
|
|
|
2016
|
93 |
C |
p. v-vi
nvt p.
|
artikel
|
| 6 |
Crizotinib-induced fatal fulminant liver failure
|
van Geel, Robin M.J.M.
|
|
2016
|
93 |
C |
p. 17-19
3 p.
|
artikel
|
| 7 |
Editorial Board
|
|
|
2016
|
93 |
C |
p. iii-
1 p.
|
artikel
|
| 8 |
Impact of preoperative 18F-FDG PET/CT on survival of resected mono-metastatic non-small cell lung cancer
|
Tönnies, Simone
|
|
2016
|
93 |
C |
p. 28-34
7 p.
|
artikel
|
| 9 |
Induction therapy followed by surgical resection in Stage-III thimic epithelial tumors: Long-term results from a multicentre analysis of 108 cases
|
Cardillo, Giuseppe
|
|
2016
|
93 |
C |
p. 88-94
7 p.
|
artikel
|
| 10 |
Inter-reader reproducibility of dynamic contrast-enhanced magnetic resonance imaging in patients with non-small cell lung cancer treated with bevacizumab and erlotinib
|
van den Boogaart, Vivian E.M.
|
|
2016
|
93 |
C |
p. 20-27
8 p.
|
artikel
|
| 11 |
K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature
|
Mengoli, Maria Cecilia
|
|
2016
|
93 |
C |
p. 55-58
4 p.
|
artikel
|
| 12 |
Medical treatment involving investigational drugs and genetic profile of thymic carcinoma
|
Asao, Tetsuhiko
|
|
2016
|
93 |
C |
p. 77-81
5 p.
|
artikel
|
| 13 |
Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer
|
Tan, Chee-Seng
|
|
2016
|
93 |
C |
p. 59-68
10 p.
|
artikel
|
| 14 |
PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors
|
Meniawy, Tarek M.
|
|
2016
|
93 |
C |
p. 9-16
8 p.
|
artikel
|
| 15 |
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy
|
Pérol, Maurice
|
|
2016
|
93 |
C |
p. 95-103
9 p.
|
artikel
|
| 16 |
Small-cell lung cancer in never-smokers: A case series
|
Tavares e Castro, Ana
|
|
2016
|
93 |
C |
p. 82-87
6 p.
|
artikel
|
| 17 |
Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer
|
Horiike, Atsushi
|
|
2016
|
93 |
C |
p. 43-46
4 p.
|
artikel
|
| 18 |
The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors
|
Chen, Yu-Mu
|
|
2016
|
93 |
C |
p. 47-54
8 p.
|
artikel
|
Tijdschrift beschrijving